StockNews.com Upgrades Immunic (NASDAQ:IMUX) to “Hold”

StockNews.com upgraded shares of Immunic (NASDAQ:IMUX) from a sell rating to a hold rating in a research note issued to investors on Friday.

Separately, Brookline Capital Management reissued a buy rating and issued a $10.00 target price on shares of Immunic in a research report on Friday, April 5th.

Immunic Trading Down 7.1 %

NASDAQ:IMUX opened at $1.18 on Friday. Immunic has a one year low of $0.95 and a one year high of $3.11. The firm’s fifty day moving average price is $1.33 and its two-hundred day moving average price is $1.27.

Immunic (NASDAQ:IMUX) last released its quarterly earnings data on Thursday, February 22nd. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.03. On average, sell-side analysts forecast that Immunic will post -0.99 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. RTW Investments LP lifted its holdings in shares of Immunic by 0.9% in the third quarter. RTW Investments LP now owns 4,335,255 shares of the company’s stock worth $6,373,000 after acquiring an additional 40,796 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of Immunic by 26.8% in the third quarter. Acadian Asset Management LLC now owns 757,250 shares of the company’s stock valued at $1,111,000 after buying an additional 159,973 shares during the period. Sweet Financial Partners LLC acquired a new position in shares of Immunic in the fourth quarter valued at approximately $45,000. Innovis Asset Management LLC increased its stake in shares of Immunic by 46.3% in the third quarter. Innovis Asset Management LLC now owns 272,457 shares of the company’s stock valued at $401,000 after buying an additional 86,217 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of Immunic by 347.5% in the third quarter. Renaissance Technologies LLC now owns 130,665 shares of the company’s stock valued at $413,000 after buying an additional 101,465 shares during the period. Institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.